The release of added context on the benefit-risk profile of CAR-T therapies underscores how safety is moving from the periphery into the category’s forefront.
It’s been a tumultuous 18 months since the passage of Medicare drug price negotiations punctured the lobbying group’s ‘aura of invincibility.’ Is it time for a policy revamp at PhRMA?
Not all of these upcoming drug launches are consensus analyst picks, but they’re all expected to create volatility in some way. Ignore them at your peril.
In this wide-ranging interview, Bayer’s head of digital transformation Saskia Steinacker shares her top tips for implementing a genAI roadmap in commercial.
Pharma has little visibility into the growing area of PBM fees